Home・Aktien・OPKO Health Inc

OPKO Health Inc

Geschlossen

BrancheGesundheitswesen

1.38 -0.72

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.38

Max

1.3900000000000001

Schlüsselkennzahlen
By Trading Economics
Einkommen	46M -8.4M
Verkäufe	39M 164M
EPS	-0.01
Gewinnspanne	-5.145
Angestellte	2,275
EBITDA	40M 12M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+117.39% upside

Dividenden
By Acuity
Nächstes Ergebnis	28. Okt. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	131M 1B
Vorheriger Eröffnungskurs	2.1
Vorheriger Schlusskurs	1.38

Nachrichtenstimmung

By Acuity

23%

77%

51 / 340 Ranking in Healthcare

OPKO Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

OPKO Health Inc Prognose

Kursziel

By TipRanks

117.39% Vorteil

12-Monats-Prognose

Durchschnitt 3 USD 117.39%

Hoch 3 USD

Tief 3 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für OPKO Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für OPKO Health Inc – Dist abgegeben haben.

Stimmung

By Acuity

51 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über OPKO Health Inc

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.